论文部分内容阅读
目的:评价参附注射液与醒脑静注射液对患者心肺脑复苏(CPCR)的作用及全身炎症反应综合征(SIRS)发生率的影响。方法:选取2013年5月—2015年10月间收治的心脏骤停患者90例患者作为研究对象,并将其分为对照组43例和观察组47例;对照组患者均给予常规西医治疗,观察组患者均给予参附注射液与醒脑静注射液治疗,评价两组患者治疗后对CPCR的作用及SIRS发生率的影响。结果:两组患者经治疗后,t_1(再灌注后30 min),t_2(再灌注后60 min)时CK、CK-MB及c Tn I水平均高于t_0(复苏即刻时间)时,但观察组患者且心跳与血压恢复正常及呼吸循环系统恢复正常时间优于对照组(P<0.05);再灌注72 h(t_3)后肿瘤坏死因子(TNF-α)、超敏C反应蛋白(Hs-CRP)、白介素-6(IL-6)等炎症指标均高于对照组(P<0.05)。结论:参附注射液与醒脑静注射液用于心肺脑复苏患者,可有效预防CPRC后再灌注损伤,也降低SIRS的发生率。
Objective: To evaluate the effect of Shenfu Injection and Xingnaojing Injection on cardiopulmonary resuscitation (CPCR) and the incidence of systemic inflammatory response syndrome (SIRS) in patients. Methods: Totally 90 patients with cardiac arrest admitted to our hospital from May 2013 to October 2015 were selected and divided into control group (n = 43) and observation group (n = 47). Patients in the control group were given routine Western medical treatment, Patients in the observation group were treated with Shenfu Injection and Xingnaojing Injection, and the effect of CPFS and the incidence of SIRS in both groups after treatment were evaluated. Results: After treatment, the levels of CK, CK-MB and cTn I in t_1 (30 min after reperfusion) and t 2 (reperfusion 60 min) were higher than those in t_0 (resuscitation time) (P <0.05). The levels of tumor necrosis factor-α (TNF-α) and hypersensitive C-reactive protein (Hs-CRP) after 72 h of reperfusion were significantly higher than those of the control group CRP), interleukin-6 (IL-6) and other inflammatory markers were higher than the control group (P <0.05). Conclusion: Shenfu injection and Xingnaojing injection for cardiopulmonary resuscitation patients, can effectively prevent reperfusion injury after CPRC, but also reduce the incidence of SIRS.